Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059939 | 0.94 | MAPT (0.56) | MAPTCYP3A4MAPK1POLBLMNA | |
| SCHEMBL3054634 | 0.91 | MAPT (0.63) | MAPTCYP3A4MAPK1POLBLMNA | |
| SCHEMBL7792084 | 0.84 | MAPT (0.55) | MAPTCYP3A4MAPK1POLBLMNA | |
| SCHEMBL3835000 | 0.84 | MAPT (0.67) | MAPTCYP3A4MAPK1POLBLMNA | |
| SCHEMBL7470399 | 0.83 | MAPT (0.61) | MAPTCYP3A4MAPK1POLBLMNA | |
| SCHEMBL7475387 | 0.83 | MAPT (0.61) | MAPTCYP3A4MAPK1TSHRTDP1 | |
| SCHEMBL3051207 | 0.82 | MAPT (0.52) | MAPTCYP3A4MAPK1POLBLMNA | |
| SCHEMBL3047176 | 0.81 | CYP3A4 (0.56) | MAPTCYP3A4MAPK1LMNATSHR | |
| SCHEMBL5692170 | 0.80 | MAPT (0.43) | MAPTCYP3A4MAPK1POLBLMNA | |
| SCHEMBL3050952 | 0.80 | MAPT (0.46) | MAPTCYP3A4MAPK1POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148893-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | claimed |
| US-20100222434-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-02 | — | — | US | disclosed |
| EP-2210603-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING THE ACCUMULATION OF AMYLOID- B PROTEIN | Sumitomo Chemical Company, Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20060148893-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | disclosed |
| EP-1654221-A2 | ANILINE DERIVATIVED ANDROGEN-, GLUCOCORTICOID-, MINERALCORTICOID- AND PROGESTERONE- RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005000795-A2 | ANILINE DERIVATIVED ANDROGEN-, GLUCOCORTICOID-, MINERALCORTICOID- AND PROGESTERONE- RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222434-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION | APP, PSEN1, BACE1 | MAPT 10/4885CYP3A4 3707/4885MAPK1 1024/4885 |
| US-20060148893-A1 | Chemical compounds | NR3C2, NR5A1, NR3C1 | MAPT 1877/4885CYP3A4 180/4885MAPK1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.